KPV vs KLOW: Same KPV Dose, Three Extra Peptides, and Which One Fits

Every figure is an all-in monthly price covering the medication, physician review, refill management and shipping. There is no separate membership fee. KLOW costs $30 a month more than KPV alone. Current pricing always lives on each product page.

What it is

KPV is a tripeptide, three amino acids long: lysine, proline and valine, which is where the name comes from. It is the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH), positions 11 to 13 of that thirteen-amino-acid hormone. Alpha-MSH drives pigmentation, but it also works as an anti-inflammatory signal. A 2008 review in Endocrine Reviews set out that the three-amino-acid tail kept much of the anti-inflammatory activity in cell and animal models, while pigmentation depends on a different part of the sequence. KPV is that tail on its own. The full reference is at what is KPV.

How it is described to work

• Entry through PepT1. A 2008 paper in Gastroenterology reported that KPV is carried into intestinal cells by PepT1, the transporter the gut lining uses to absorb small peptides, and that its effect depended on the transporter.
• NF-kB and MAPK. Inside the cell, it is described as interfering with the NF-kB and MAPK pathways that turn an inflammatory trigger into an inflammatory response.
• Lower cytokine output. In cell and mouse work, less TNF-alpha, IL-6, IL-1beta and IL-8.
• No melanocortin-1 receptor. A 2012 paper using a human bronchial cell line described it working through a route that did not depend on the receptor that drives pigmentation, which is why KPV is not a tanning peptide.

All of that work is in cells and animals.

One variable or four

The practical trade-off is the one that applies to every blend. KPV alone is one variable, which makes it easier to judge whether it is doing anything. KLOW is four actives in a fixed ratio that cannot be adjusted per component; if one of the four does not suit you, the whole vial has to change. A blend is a convenience for people who already want all four, not a stronger version of any one of them.

There are no randomised controlled trials of KPV in humans, and no human trials of KLOW or of any four-peptide combination of its components. KPV's evidence is cell work, including human intestinal, T-cell and bronchial epithelial cell lines, and mouse models: the 2008 Inflammatory Bowel Diseases and Gastroenterology colitis papers, a 2017 nanoparticle formulation study in Molecular Therapy, and a 2013 PLoS One brain-injury study. Most of the gut work gave KPV orally, so it does not establish what a subcutaneous injection does.

KLOW's evidence is per component and uneven. GHK-Cu has small human studies, mostly of topical application to skin, none with the injectable form. BPC-157 has early-phase human work for inflammatory bowel indications and none for tendon injury. TB-500 has no human trials; the early-phase human work was on full-length thymosin beta-4. No study has compared KLOW with its components, so nothing shows that four together do more than one alone.

KLOW has no regulatory status of its own; the FDA regulates the bulk substances, not the blend. As of the FDA pages checked in September 2026:

A committee vote is a recommendation, not a decision. All four remain legal to prescribe and dispense as compounded medications, and compounded medications are not FDA approved. Are peptides FDA approved explains the difference.

Both are injected under the skin (subcutaneously), usually into the abdomen or thigh, rotating sites, at 0.25 mL, which is 25 units on a U-100 insulin syringe, Monday through Friday with weekends off. KLOW's directions specify mornings. Twenty doses per 5 mL vial covers about four weeks, which is why refills run every 28 days, one vial per fill. You do not need to calculate anything: your directions are printed on the vial, and your physician sets them after reviewing your intake.

Both ship refrigerated with ice packs, along with sterile syringes and alcohol prep pads, and stay in the fridge between doses. More detail is on KPV dosage and KLOW dosage.

KPV. Mostly injection-site redness, mild soreness or occasional bruising. Some people report mild nausea or a transient headache early on. Animal work has not reported toxicity at the doses studied, but there are no human trials. More at KPV side effects.

KLOW. The same injection-site pattern, and some people report nausea or light-headedness early on. GHK-Cu delivers copper, so anyone with Wilson's disease or another copper-metabolism disorder should not take it, and high-dose zinc supplements compete with copper. More at KLOW side effects.

Neither is expected to darken skin, because KPV lacks the pigmentation part of alpha-MSH. For any reaction that is severe, spreading, or involves difficulty breathing, call 911, then message your care team.

Neither can be bought legitimately without a prescription. Sites selling them "for research use only" are not accountable for what is in the vial. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A pharmacy compounds it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with your directions printed on the vial.
5. Your care team stays reachable for questions.

Step-by-step pages: how to get KPV prescribed online and how to get KLOW prescribed online.